Translational & Precision Medicine (TPM) Network

Network Goals

Scientific Expertise:

The Translational & Precision Medicine (TPM) Network and associated Communities facilitate interactions among experts across multidisciplinary fields to foster translational science with a focus on individuals via patient care and society via healthcare. The interactions are through social media, email blasts, and teleconferences with focused scientific content.

Catalyst for Innovation:

The TPM Network is a catalyst for innovation by sponsoring a range of scientific programs at the Annual Meeting focused on translational and precision medicine.

Influence and Impact:

The TPM Network is the lead group engaged in translational and precision medicine and optimal pharmacotherapy in patient care.

Education and Communication:

The TPM Network offers educational opportunities via the Communities.

Organizational Effectiveness:

Leadership within TPM is expanded by a Network Steering Committee.
The TPM Network has regularly scheduled teleconferences and utilizes social media to engage members throughout the year.
The TPM Network fosters the career of its members by assisting Communities in recognizing members for individual achievements and contributions to ASCPT, sponsoring educational programming in translational and precision medicine, and providing opportunities for networking activities throughout an individual’s career.

ASCPT Members-Only Webinar Presented by the Special Populations (SPO) Community
Title: Ethnic Diversity and Drug Response: Drug Development Consequences
Date and Time: Thursday, January 21, 2021, 3:30 pm ET
Speaker: Annette Gross, PhD
Moderators: Elimika Pfuma Fletcher, PharmD, PhD, and Pooja Manchandani, PhD
Description: This presentation will provide an overview of inter-ethnic differences in drug response, inclusive of the intrinsic and extrinsic factors which can be associated with population differences in pharmacokinetics, pharmacodynamics, efficacy, and safety. Drug development considerations will be discussed in relation to potential inter-ethnic differences in drug response including relevant regulatory guidelines (e.g., ICH E5, ICH E17) and assessment of ethnic sensitivity, US Food & Drug Administration Clinical Trial Diversity initiative, requirements for clinical trial data in specific countries / ethnic groups, and implications for drug development strategies and design of clinical studies (e.g., Multiregional Clinical Trials, Bridging Studies).
Registration Link: https://us02web.zoom.us/webinar/register/3116098729528/WN_YVZtagb4TRexjOoRG3cxNg